Blog

In the Age of AI, Doctors Need to Learn From Doctors More Than Ever

Roman Giverts — Tue, 10 Nov 2026 14:52:27 GMT

As AI moves deeper into clinical practice, a legitimate concern has followed it: If physicians can retrieve an answer in seconds, will they lose some of the expertise that once came from working through the question themselves?

There are already reasons to take that concern seriously. A 2025 study in The Lancet Gastroenterology & Hepatology found that endoscopists who had grown accustomed to AI assistance detected fewer precancerous growths when they later worked without it.

AI is also changing how physicians learn. Studies, guidelines and treatment options that once took hours to find can now be retrieved and summarized in seconds. But while finding information has gotten faster, clinical judgment still develops the way it always has: through experience.

That process can take years.

An IQVIA analysis found that the median time for oncologists to adopt a new therapy is 3.5 years, while only 20 percent consistently prescribe a new therapy within its first two years on the market. Much of that time is spent building the clinical confidence to put new evidence into practice.

Consider pancreatic cancer. At ASCO this year, the Phase 3 RASolute 302 trial reported a near doubling of survival time. Oncologists could find the results immediately. The study alone couldn't tell them which patients were the best candidates, where the treatment should fit in the existing sequence, or what they should watch for when they began using it.

Those decisions draw on something physicians have always relied on: the experience of other physicians.

Evidence-based medicine combines published evidence, clinical expertise and patient preferences. AI is becoming extraordinarily good at retrieving and synthesizing the first. It can also make the accumulated experience of physicians easier to find and learn from.

We're beginning to see that behavior on Vumedi. The physicians who use our AI tools most heavily also spend the most time learning from other physicians. Over the past four years, as AI has rapidly entered medicine, the amount of time active physicians spend learning from peers on Vumedi has risen from about 20 minutes a month to 52 minutes. AI use isn't displacing peer learning – it’s deepening it.

Now those two behaviors are beginning to converge – generative AI answers and peer learning. A physician can ask AI a clinical question and hear how experienced colleagues have approached the same decision, where they agree, where they differ and what experience has taught them beyond what appears in an abstract or guideline.
At Vumedi, when a physician asks a question, AI finds relevant moments across more than 2 million minutes of expert video where physicians have addressed it. Instead of replacing the process of learning from colleagues, AI makes those colleagues easier to find.

A physician who has heard experienced colleagues reason through difficult cases is also better equipped to interrogate an AI-generated answer, recognize what it leaves out and decide whether it applies to a particular patient. The expertise AI has been accused of weakening may, in fact, be what allows physicians to use it safely and well.

AI is making the evidence behind new therapies, devices and procedures available almost instantly, and it should become an essential reference tool for every physician. But evidence alone doesn’t change practice. The more physicians rely on AI, the more learning from peers matters. It builds the judgment to put new evidence to work and to recognize when an AI-generated answer is wrong.

AI can put the evidence in front of a physician in seconds. Knowing what to do with it still comes from experience and learning from other doctors.

Breast Cancer’s Busiest Year: Where Physician Education Has to Catch Up

Sameh Abdelmalak — Tue, 03 Nov 2026 17:31:58 GMT

Every October, Breast Cancer Awareness Month puts screening and early detection in the spotlight. This year there’s a second story underneath it. Since December 2025, the FDA has approved 12 new breast cancer drugs and indications, more new therapy in under a year than most physicians can absorb on their own.

Every approval opens an education gap. Physicians have to learn which patients qualify, how a new drug fits with the ones they already use, and how to manage its side effects. And that learning can’t stop at the oncologist. About 322,000 American women will be diagnosed with invasive breast cancer this year, and their care runs through family physicians, internists, OB-GYNs and radiologists as well as surgeons and oncologists.

On Vumedi, more than 640,000 healthcare professionals share expertise through video, podcasts and community. So far this year, over 13,000 physicians from more than 30 specialties have watched breast cancer content on Vumedi, starting videos 48,740 times.

Here’s what we’re seeing as they work through breast cancer’s busiest year, and what it means for anyone helping physicians keep up.

A landmark year in treatment

Since December 2025, the FDA has approved 12 new breast cancer drugs and indications, and six of them are antibody-drug conjugates (ADCs). Together they reach every major subtype: HER2-positive, triple-negative and hormone receptor-positive disease.

We’ve been watching how oncologists talk about these drugs. Using AskMedi, our AI-powered clinical intelligence tool, we analyzed more than 18 months of physician-to-physician discussion on Vumedi about ADCs in breast cancer. The question has moved from “do ADCs work?” to “which ADC, when, and how do we keep patients safely on treatment?” Three shifts stand out.

ADCs moved from last resort to first line. ADCs were once reserved for patients who had run out of options. Enhertu is now approved first line in metastatic HER2-positive disease and, since May, before and after surgery in early-stage disease. Trodelvy and Datroway are now first-line options in metastatic triple-negative breast cancer. On Vumedi, Dr. Harold Burstein and Dr. Lindsay Northrop describe U.S. practice in which “almost every flavor or subset of breast cancer” makes a patient an ADC candidate at some point.
More options mean harder sequencing decisions. With several ADCs available for the same patient, the question is which to use first and what comes next. Dr. Barbara Pistilli notes there is still no head-to-head trial and no validated biomarker to answer it, so physicians are making those calls ahead of formal evidence. Dr. Sara Tolaney adds that managing toxicity, including interstitial lung disease, is now inseparable from the efficacy conversation.
Blood tests are changing when doctors switch therapy. In the trial behind camizestrant’s September approval, patients switched treatment when a circulating tumor DNA test found an ESR1 resistance mutation, before scans showed progression. Median progression-free survival was 16.8 months versus 9.2. Oral agents like vepdegestrant added more targeted choices for hormone receptor-positive disease.More is coming: giredestrant, another oral endocrine therapy, has an FDA decision date of December 18, 2026.

What this means for education: When there’s no head-to-head trial or validated biomarker to settle a question, physicians learn from the colleagues already using these drugs. Peer-to-peer education fills that gap long before guidelines catch up.

On Vumedi, oral SERDs and endocrine therapy drew the most viewing of any breast cancer topic this past quarter, followed by ADCs. Viewing across most topics dipped after the summer conference season, but the number of physicians watching oral SERD content held steady.

The audience is bigger than oncology

A breast cancer therapy doesn’t only reach oncologists. Patients pass through primary care and women’s health before they’re diagnosed, and they keep seeing those physicians throughout treatment.

Screening and dense breasts. Screening now starts at 40 under the USPSTF’s 2024 update, and since September 2024 every mammography report tells patients whether their breasts are dense and that dense tissue can hide cancer. What to do next is still unsettled: the USPSTF finds the evidence insufficient for supplemental imaging, while the American College of Radiology recommends MRI for some women. At Vumedi Week 2026, Dr. Romuald Ferre walked through an ASCO/ACR decision tree for choosing supplemental MRI or contrast-enhanced mammography, a question for the radiologist and for the primary care physician or OB-GYN deciding what to order.

Risk and prevention. About 1 in 8 American women will develop breast cancer, and incidence in women under 50 is rising about 1.4% a year. The ACR recommends a risk assessment by age 25, and the USPSTF recommends offering risk-reducing medication to women at increased risk. Those decisions sit with family physicians, internists and OB-GYNs. On Vumedi, genetics and BRCA was the only breast cancer topic to grow from the second quarter to the third, with video starts up 30%.

Co-managing patients during treatment. While a patient is on an ADC or years of endocrine therapy, her primary care physician or gynecologist is still prescribing for other conditions and fielding new symptoms, such as a cough that could signal interstitial lung disease. Dr. Makeba Williams’ Vumedi session on nonhormonal and local estrogen strategies for breast cancer survivors is the kind of guidance an OB-GYN needs when a patient on endocrine therapy asks for relief from hot flashes.

What this means for education: A new therapy needs an education plan that reaches the physicians who screen, refer and co-manage, not only the ones who prescribe it.

Oncologists are the most engaged audience by far. Hematology-oncology physicians start about 10 breast cancer videos each, more than six times as many as primary care physicians, and account for about two-thirds of all viewing. But they aren’t the only ones watching. Vumedi’s internists and family physician audiences are the largest group of viewers, at 45%, followed by hematology-oncology at 24% and cardiology at 12%. The cardiology audience reflects how often breast cancer care now crosses into heart health, from monitoring cardiac function on HER2-targeted therapy to managing cardiovascular risk on long-term endocrine therapy. In all, more than three-quarters of the physicians watching breast cancer content aren’t oncologists, even though most of it is still made with oncologists in mind.

Advances only matter when they reach patients

Breast cancer treatment is advancing faster than ever, and so is what it asks of the clinicians caring for patients. From the first mammogram at 40 to the choice between two ADCs, physicians across specialties are making decisions where the evidence is still moving.

As Vumedi Chief Content Officer Jo-Ann Strangis puts it: "The goal is to get the latest medical advances into patient care as quickly and thoughtfully as possible." That happens fastest when physicians learn directly from each other.

Innovators and industry partners: Partner with Vumedi to educate the physicians across specialties who will prescribe, refer for and co-manage your therapy.
Healthcare professionals: Join Vumedi to learn from leading experts, or consider sharing your expertise with more than 640,000 colleagues by contributing content..

Meet Vumedi: The Peer to Peer Learning Community

Vumedi — Tue, 03 Nov 2026 17:17:41 GMT

What Vumedi is, how clinicians use it, and why peer-to-peer medical learning matters more than ever.

Welcome to the Vumedi blog!

Since this is our first post, let’s start with introductions: who we are, what we do and why we believe so strongly in clinicians learning from one another.

First, the basics. It’s pronounced “view-med-ee.” The name comes from a simple idea: a place where clinicians can view medical education. But there’s another kind of view that matters just as much: the views of clinicians themselves. How they interpret new evidence, evaluate treatments and approach decisions in clinical practice.

For 17 years, Vumedi has helped clinicians learn from clinicians. What began as a video library has grown into a peer-to-peer medical learning community where clinicians learn through expert-led videos, podcasts and AI-powered tools.

Today, more than 640,000 registered clinicians in more than 21 medical specialties are part of the Vumedi community. Every month, physicians spend more than 4.3 million minutes engaging with educational content on the platform. The average active physician spends 52 minutes learning on Vumedi each month.

Why do physicians invest that time? Because medicine is advancing quickly, and staying current with new evidence is only part of the challenge. Clinicians also want to understand how their peers are interpreting research, evaluating new therapies and putting medical advances into practice.

Vumedi is built to answer that need, making expert insight and peer-to-peer learning available beyond any one institution, conference or professional network.

Why peer-to-peer medical education matters

Medicine has always advanced through clinicians sharing what they know.

A surgeon demonstrates a new technique. An oncologist explains how emerging trial data is influencing treatment decisions. A neurologist shares experience with a recently approved therapy. These conversations show how advances in medicine translate into patient care.

Published research and clinical guidelines are essential, but they can't capture every question clinicians face in practice. How are colleagues selecting patients for a new treatment? What challenges are they seeing? How are they weighing different approaches when the evidence is still evolving?

Hearing from colleagues who have faced the same questions provides context a journal article can’t.

As medical innovation accelerates, that exchange matters more than ever. Vumedi brings these perspectives together, so clinicians can hear directly from the experts researching, evaluating and applying new approaches to care.

Frequently asked questions about Vumedi

What is Vumedi used for?

Physicians and other clinicians use Vumedi to stay current with medical advances, explore new treatments and clinical trial results, learn procedural techniques and hear how colleagues approach complex clinical patient cases and questions.

Educational content spans more than 21 medical specialties, including oncology, cardiology, neurology, endocrinology, pulmonology, rheumatology and surgery.

Clinicians can watch expert-led videos, listen to medical podcasts and use AI-powered tools to find relevant information and physician perspectives.

Who creates the medical education on Vumedi?

Vumedi connects clinicians with educational content from respected physicians, researchers, academic medical centers and professional organizations.

The platform features expertise from institutions including Mayo Clinic and Cleveland Clinic, alongside physician-led podcasts such as Oncology Brothers and The Curbsiders. Clinicians can also explore clinical trial findings and educational discussions from researchers and pharmaceutical companies.

With more than 640,000 registered clinicians across over 21 medical specialties, Vumedi brings together a broad range of expert voices and clinical perspectives, helping physicians learn from colleagues beyond their own institutions and professional networks.

Is Vumedi free for doctors?

Eligible physicians and healthcare professionals can register for free access to Vumedi's medical education resources, including expert-led videos, podcasts and other educational content.

The platform is designed for healthcare professionals rather than patients or the general public.

Who can join Vumedi?

Vumedi is intended for physicians, advanced practice providers (APPs), residents, fellows, medical students and other eligible healthcare professionals.

Registration includes professional information used to establish eligibility for the clinical learning community. Clinicians may be asked to provide credentials or other qualifying information as part of verification.

What kinds of medical education are available on Vumedi?

Vumedi offers expert-led educational videos, medical podcasts and clinical discussions covering a broad range of specialties and disease states.

Topics include emerging therapies, clinical trial findings, evolving treatment algorithms, surgical and procedural techniques, and practical approaches to patient care.

Physicians can also explore educational content from medical conferences, hear researchers discuss new findings and learn how experienced colleagues are applying evidence in clinical practice.

How much time do physicians spend learning on Vumedi?

Physicians collectively spend more than 4.3 million minutes per month engaging with educational content on Vumedi.

The average active physician spends 52 minutes on the platform monthly, exploring new therapies, emerging research, treatment approaches and other topics relevant to their specialties.

Physician engagement continues to grow. Annual video starts increased 41%, from approximately 4.6 million to 6.5 million, reflecting growing use of expert-led medical education.

How does Vumedi AI help physicians find and learn from medical expertise?

Vumedi’s AI-powered tools help clinicians navigate a large and growing library of medical education, find specific information within videos and podcasts, and explore what different experts are saying about a clinical topic.

With AI-powered search, clinicians can find relevant content across the platform. They can generate summaries of videos and jump directly to timestamped moments in video and audio where an expert addresses a particular question, treatment or finding.

Through Ask Vumedi, clinicians can ask questions and explore responses that bring together perspectives from multiple physicians. Rather than relying on a single expert’s interpretation, they can discover common themes, differences in approach and a cross-section of viewpoints represented in the educational content.

For example, an oncologist exploring a new therapy might want to hear how different experts are interpreting trial results, which patients they consider appropriate candidates and where uncertainty remains. AI helps surface those conversations and makes it easier to go directly to the original expert content.

More than 150,000 clinicians have engaged with Vumedi’s AI capabilities, generating over 1 million interactions.

How does Vumedi make money?

Vumedi works with pharmaceutical, biotechnology and other life sciences companies, along with their agency partners, to support physician education and engagement programs.

These partnerships help life sciences organizations reach relevant physician audiences, share educational information and better understand the clinical topics attracting physician attention.

Vumedi’s commercial business supports its broader medical learning platform and community.

Is it Vumedi or VuMedi?

You'll sometimes see our name written as “VuMedi,” including in older references to the company. That was our original branding, but today our official name is Vumedi, with a lowercase “m.”

Same company, same commitment to physician learning. Just an updated name.

How can doctors join Vumedi?

Physicians and eligible healthcare professionals can register at vumedi.com to explore the platform's medical education resources.

Medical experts, institutions and professional societies interested in publishing educational content, as well as life sciences organizations exploring partnership opportunities, can also connect with the Vumedi team.

How Vumedi is expanding medical education beyond video

Video remains central to Vumedi, but the ways clinicians learn on the platform continue to expand.

The podcast library has grown more than sixfold, giving clinicians more opportunities to hear expert conversations and clinical perspectives in a format that fits their schedules.

AI-powered search, video summaries and timestamped navigation make that growing library easier to explore, so clinicians can get to the moment that answers their question.

These developments reflect how clinicians’ learning needs are evolving. Different clinical questions call for different kinds of educational experiences, and clinicians increasingly expect to find relevant information and expertise when and where they need it.

For Vumedi, the goal remains consistent even as the technology and formats evolve: help clinicians learn from one another and bring new medical knowledge into practice.

What to expect from the Vumedi blog

We're launching this blog to explore the ideas, evidence and conversations shaping how physicians learn and how medicine advances.

We'll share perspectives on medical innovation, physician learning, emerging technologies like AI, and the trends we're seeing across the Vumedi community. You'll also hear from Vumedi leaders, medical experts and partners about the opportunities and challenges facing healthcare education.

With hundreds of thousands of clinicians learning across more than 21 specialties, we have a unique view of what clinicians are learning, which topics are drawing their attention and how educational needs are evolving. This blog will be a place to share those insights and explore what they mean for physicians, healthcare organizations and the life sciences industry.

Whether you're a clinician, medical expert, healthcare institution, professional society or life sciences partner, we're glad you're here.

Welcome to Vumedi. We look forward to learning together.

Are you a clinician? Register for free to start learning from your peers. Work in life sciences? See how Vumedi partners with brands to support physician education.